Zobrazeno 1 - 10
of 645
pro vyhledávání: ''
Autor:
Daneng Li, Nicolas Sommer, Wendy Verret, Riad Salem, Riccardo Lencioni, Sairy Hernandez, Beiying Ding
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5437-5447 (2021)
Cancer Medicine
Cancer Medicine
Background IMbrave150 is a phase III trial that assessed atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC) and demonstrated a significant improvement in clinical outcomes. Explo
Publikováno v:
Journal of Immunotherapy. 44:234-238
Immunotherapy has revolutionized the treatment of advanced cutaneous squamous cell carcinoma. However, the role of immune checkpoint inhibitors for the treatment of Marjolin ulcer (MU), a rare cutaneous malignancy that arises from previously traumati
Autor:
Ze-Man Cai, Qingxin Cai, Ying-Ji Hong, Zhixiong Lin, Kai-Chun Huang, Cui-Dai Zhang, Mei Li, Zhining Yang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 12, Pp 3886-3895 (2021)
Cancer Medicine, Vol 10, Iss 12, Pp 3886-3895 (2021)
To compare the efficacy and safety of induction chemotherapy (IC) followed by intensity‐modulated radiotherapy (IMRT) alone versus concurrent CCRT in locoregionally advanced nasopharyngeal carcinoma (LA‐NPC). Patients with newly diagnosed stage I
Autor:
Bart A. van de Wiel, Judith M. Versluis, Robyn P. M. Saw, Sydney Ch'ng, C. Blank, Bastian Schilling, Irene L.M. Reijers, Richard A. Scolyer, Georgina V. Long, Michel W.J.M. Wouters, Alexander C.J. van Akkooi, Elisa A. Rozeman, Alexander M. Menzies
Publikováno v:
European Journal of Cancer. 148:51-57
Background Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases. Neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and an impre
Autor:
Shidai Jin, Renhua Guo, Fangyan Gao, Liang Chen, Zhihong Zhang, Qianqian Wang, Jingya Zhang, Wen Gao, Fan Lin, Chen Zhang, Tianyu Qu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
Background To compare the benefits and explore the cause of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and its combination with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients har
Autor:
Aileen Deng, Jordan M. Winter, Charles J. Yeo, Chun Wang, Atrayee Basu Mallick, Steven J. Cohen, James Posey
Publikováno v:
European Journal of Cancer. 147:17-28
To compare overall survival (OS) in patients who underwent surgery for early-stage pancreatic adenocarcinoma (rPca) based on sequence (NAT, neoadjuvant therapy and/or AT, adjuvant therapy) and type (SA, single-agent or MA, multi-agent) of chemotherap
Autor:
Shengxiang Ren, Lunxu Liu, Shun Xu, Ke-Neng Chen, Weimin Mao, Xiaofei Li, Wen-Zhao Zhong, Rong Yin, Bu-Hai Wang, Jian Li, Qun Wang, Shidong Xu, Cheng Huang, Yi-Long Wu, Haitao Ma, Ping Yu, Songtao Xu, Hong-Hong Yan, Jin-Ji Yang, Qing Zhou, Chun Chen, Si-Yang Liu, Ying Cheng, Fan Yang, Lin Wu, Zhidong Liu, Xue-Ning Yang, Yucheng Wei, Yongyu Liu
Publikováno v:
Journal of Clinical Oncology. 39:713-722
PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079 ), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients wit
Autor:
Hans-Peter Sinn, Christian Schem, Frederick Klauschen, Karsten Weber, Andreas Schneeweiss, Elmar Stickeler, Marion von Mackelenbergh, Dirk Michael Zahm, Sibylle Loibl, Bruno Valentin Sinn, Denise Treue, Claus Hanusch, Frederik Marmé, Clemens Becker, Michael Untch, Jenny Furlanetto, Carsten Denkert, Thomas Karn, Nicole Burchardi, Peter A. Fasching, Wolfgang D. Schmitt, Volkmar Müller
Publikováno v:
Clinical Cancer Research. 27:2584-2591
Purpose: We evaluated mRNA signatures to predict response to neoadjuvant PD-L1 inhibition in combination with chemotherapy in early triple-negative breast cancer. Experimental Design: Targeted mRNA sequencing of 2,559 transcripts was performed in for
Autor:
Vinay Raja, Micki Prager, Marc Hoffmann, Qamar J. Khan, Sheshadri Madhusudhana, Larry Beck, Lauren Nye, Rajvi H. Shah, Jaimie Heldstab, Dinesh Pal Mudaranthakam, Stephanie LaFaver, Roy A. Jensen, Roberto Rodríguez, Kelsey E. Larson, Gregory James Crane, Amanda L. Amin, Richard McKittrick, Venkatadri Beeki, Joshua M Staley, Lindsey Prochaska, Roberto Salgado, Maureen Sheehan, Rachel Yoder, Andrew K. Godwin, Manana Elia, Bruce F. Kimler, Larry Corum, Anuj Shrestha, Priyanka Sharma, Kathan Mehta, Christa R. Balanoff, Deepti Satelli, Jamie L. Wagner, Anne O'Dea, Milind A. Phadnis, Robert Pluenneke, Yen Y. Wang, Karissa Finke
Publikováno v:
Clin Cancer Res
Purpose: Addition of carboplatin (Cb) to anthracycline chemotherapy improves pathologic complete response (pCR), and carboplatin plus taxane regimens also yield encouraging pCR rates in triple-negative breast cancer (TNBC). Aim of the NeoSTOP multisi
Autor:
Tom Wei-Wu Chen, Herbert H. Loong, Sze Huey Tan, Alex K.C. Leung, Richard Quek, Chih Chi Chang, Angela Pang, Myo Myint Maw, Takeshi Hirose, Makoto Endo, Akira Kawai, Mark E. Puhaindran, Virote Sriuranpong, Siyamol Mingmalairak, Mohamad Farid, Jeffrey C.H. Chan, Wei Lin Goh, Roger K.C. Ngan
Publikováno v:
Cancer Science
Angiosarcoma (AS) is a rare disease with a dismal prognosis. The treatment landscape and prognostic factors for advanced AS, including locally advanced, unresectable, and metastatic disease remain elusive. The Asian Sarcoma Consortium is an internati